FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 20, 2024

 

bdpt_8kimg2.jpg

 

BIOADAPTIVES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

000-54949

 

46-2592228

(State or Other Jurisdiction

of Incorporation) 

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2620 Regatta Drive, Suite 102

Las Vegas, Nevada 89128

(Address of Principal Executive Office) (Zip Code)

 

(702) 659-8829

Registrant's telephone number, including area code: 

 

N/A

(former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01: Other Events.

 

On November 20, 2024, FINRA approved BioAdaptives Inc.’s Reverse split. The reverse split becomes effective on November 21, 2024.

 

Item 7.01 Regulation FD Disclosure

 

FINRA requires a letter to the shareholders regarding the Company issued a press release on October 29, 2024, reporting the impending reverse split.

 

A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number

 

Exhibit Description

 

 

 

99.1

 

Press Release

 

 
2

 

 

SIGNATURE

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

November 20, 2024

 

BioAdaptives, Inc.

 

 

 

 

 

 

 

/s/ James Keener

 

 

 

James Keener

 

 

 

Director and CEO

 

 

 
3

 

 

nullv3.24.3
Cover
May 20, 2024
Cover [Abstract]  
Entity Registrant Name BIOADAPTIVES, INC.
Entity Central Index Key 0001575142
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date May 20, 2024
Entity File Number 000-54949
Entity Incorporation State Country Code DE
Entity Tax Identification Number 46-2592228
Entity Address Address Line 1 2620 Regatta Drive
Entity Address Address Line 2 Suite 102
Entity Address City Or Town Las Vegas
Entity Address State Or Province NV
Entity Address Postal Zip Code 89128
City Area Code 702
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Local Phone Number 659-8829
Bioadaptives (PK) (USOTC:BDPT)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Bioadaptives (PK).
Bioadaptives (PK) (USOTC:BDPT)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Bioadaptives (PK).